{ "schemaVersion": 2, "eyebrow": "Genitourinary Oncology", "title": "Bladder Cancer", "summary": "Stage-directed bladder cancer management hinges on complete transurethral staging, separation of non-muscle-invasive from muscle-invasive disease, risk-adapted intravesical therapy, and timely cystectomy or chemoradiation when curative local treatment is indicated.", "seoDescription": "Physician guide to staging and treating non-muscle-invasive, muscle-invasive, node-positive, and metastatic bladder cancer.", "clinicalQuestion": "How should physicians stage and select definitive treatment for bladder cancer across non-muscle-invasive, muscle-invasive, and advanced disease?", "specialty": "Urology and Medical Oncology", "audience": "U.S. physicians and medical trainees", "tags": [ "bladder cancer", "NMIBC", "muscle-invasive bladder cancer", "TURBT", "BCG", "radical cystectomy", "trimodality therapy", "urothelial carcinoma" ], "keyTakeaways": [ "A complete TURBT that establishes stage and grade is the pivotal branch point: Ta, T1, and carcinoma in situ are managed as NMIBC, whereas cT2-T4 disease requires curative-intent muscle-invasive pathways. [13][16]", "High-risk NMIBC is generally treated with TURBT followed by intravesical BCG; highest-risk features or BCG-unresponsive high-grade disease should trigger counseling about radical cystectomy rather than repeated ineffective bladder-sparing treatment. [1][14][16][24]", "For cT2-T4aN0M0 disease, cisplatin-based neoadjuvant chemotherapy before radical cystectomy is standard and confers an approximately 5% absolute 5-year survival benefit. [18]", "Bladder preservation for appropriately selected muscle-invasive disease is multimodal: maximal TURBT plus concurrent chemotherapy and radiation, not radiation or TURBT alone. [13]", "Do not instill BCG after traumatic catheterization, during urinary tract infection, or before adequate post-TURBT healing because these conditions increase risk of disseminated BCG infection. [23]" ], "sections": [ { "id": "initial-staging", "eyebrow": "Diagnostic Branch Point", "heading": "Establish stage before selecting treatment", "intro": "The management-defining question is whether detrusor muscle invasion or metastatic spread is present.", "paragraphs": [ "Use cystoscopic tumor documentation and TURBT pathology to assign local stage and grade. Record tumor size, multiplicity, location, appearance, prior recurrence history, prior intravesical treatment, and whether carcinoma in situ is present; these variables determine NMIBC recurrence and progression risk and guide intravesical versus definitive surgical management. [5][12][16]", "Confirm whether the TURBT specimen demonstrates Ta disease, lamina propria-invasive T1 disease, carcinoma in situ, or muscularis propria invasion. T1 high-grade disease and carcinoma in situ carry materially greater progression concern than low-grade papillary disease; carcinoma in situ is particularly important for risk stratification after grade. [11][24]", "For suspected or established muscle-invasive disease, obtain cross-sectional staging imaging as part of the initial evaluation. Before TURBT, pelvic MRI or CT urogram is preferred in trial-staging frameworks because TURBT-related inflammation can cause local overstaging; chest CT is also used for baseline staging. [5][13]" ], "bullets": [ "If gross or microscopic hematuria is the presentation, evaluate for occult urinary tract cancer rather than attributing hematuria to a benign cause without a malignancy assessment. [3]", "Urine cytology can help identify occult high-grade disease; interpret urinary biomarker positivity cautiously because false positives occur and broad validation is incomplete. [5]", "Do not use emerging artificial-intelligence pathology assays or circulating tumor DNA to determine escalation outside a validated clinical pathway; prospective evidence has not established their role in intravesical-treatment decisions. [6][14]" ], "subsections": [], "table": { "caption": "Management branch after transurethral pathology and clinical staging. [13][16][21]", "columns": [ "Clinical-pathologic branch", "Decision implication", "Next treatment direction" ], "rows": [ [ "Ta, T1, or carcinoma in situ without muscle invasion", "Non-muscle-invasive bladder cancer; recurrence and progression risk vary by grade, T1 invasion, carcinoma in situ, multiplicity, and recurrence history. [5][11][12]", "Risk-adapted intravesical therapy after TURBT; high-risk disease generally receives BCG, while selected highest-risk disease warrants cystectomy counseling. [1][14][16]" ], [ "cT2-T4aN0M0", "Clinically non-metastatic muscle-invasive bladder cancer; treat with curative intent. [13][18]", "Cisplatin-based neoadjuvant chemotherapy followed by radical cystectomy with bilateral pelvic lymphadenectomy, or selected bladder-preserving trimodality therapy. [13][18]" ], [ "Clinically node-positive or limited nodal metastatic disease", "Evidence is less definitive because these patients are commonly excluded from definitive local-treatment trials. [20]", "Use systemic therapy; in selected responders, combine with high-intensity local treatment such as cystectomy with pelvic lymph-node dissection or bladder-directed chemoradiation. [9][20]" ], [ "Distant metastatic disease", "Primary treatment is systemic; local procedures are used selectively for palliation or consolidation. [21]", "Systemic therapy options include enfortumab vedotin plus pembrolizumab, chemotherapy-immunotherapy approaches, chemotherapy, or immunotherapy; use radiation, diversion, or cystectomy for symptom-directed local control when needed. [21]" ] ] } }, { "id": "nmibc-management", "eyebrow": "Non-Muscle-Invasive Disease", "heading": "Risk-adapted treatment after TURBT", "intro": "Avoid treating all NMIBC as biologically equivalent.", "paragraphs": [ "After TURBT, use pathology and endoscopic burden to separate low-grade papillary disease from high-grade Ta, T1 high-grade, and carcinoma in situ. Most NMIBC presents as Ta, with smaller proportions presenting as T1 or carcinoma in situ, but the latter patterns drive progression risk and need for intensive intravesical treatment or early cystectomy discussion. [12][24]", "For high-risk NMIBC, TURBT followed by intravesical BCG is standard treatment. BCG reduces recurrence compared with TURBT alone and has demonstrated superior recurrence-free outcomes versus several intravesical chemotherapeutic regimens in high-risk disease. [1][23]", "Counsel patients with the highest-risk NMIBC features regarding radical cystectomy as an oncologically definitive alternative to BCG-based preservation. In high-risk T1 disease and/or carcinoma in situ that fails BCG, progression risk has been reported as high as 50%; immediate cystectomy offers the best survival opportunity but carries major quality-of-life consequences related to urinary diversion and loss of the native bladder. [14][24]" ], "bullets": [ "For low-risk disease, favor intravesical chemotherapy rather than BCG when intravesical treatment is used, given BCG toxicity considerations. [24]", "For intermediate-risk disease, BCG is used when intravesical chemotherapy is unsuccessful; high-risk disease is the principal setting for first-line BCG. [24]", "After BCG failure, distinguish low-grade recurrence from recurrent high-grade T1 disease or carcinoma in situ: low-grade failure can be managed with intravesical chemotherapy, whereas high-grade failure should prompt cystectomy-focused counseling or an alternative bladder-preserving strategy when cystectomy is declined or unsuitable. [24]" ], "subsections": [ { "heading": "BCG-unresponsive high-risk disease", "paragraphs": [ "BCG-unresponsive high-risk NMIBC is a high-priority escalation state because no established intravesical salvage therapy has historically provided reliably effective disease control. Radical cystectomy remains the definitive option for appropriate surgical candidates. [4][24]", "Pembrolizumab monotherapy has been studied for BCG-unresponsive high-risk NMIBC in patients pursuing a bladder-sparing approach; use systemic checkpoint inhibition only within the specific disease setting and eligibility represented by its clinical evidence, rather than as routine therapy for BCG-naive NMIBC. [1][2]" ], "bullets": [ "Do not delay reassessment of recurrent high-grade disease merely because cystoscopy appears limited; obtain pathologic confirmation with repeat resection or directed biopsy when visible or cytologic evidence suggests persistent high-grade disease. [5][16]", "Present bladder-sparing salvage as a tradeoff against earlier definitive cystectomy, particularly for persistent T1 high-grade disease or carcinoma in situ. [4][24]" ] }, { "heading": "BCG safety before each instillation", "paragraphs": [ "Withhold intravesical BCG when traumatic catheterization, concurrent urinary tract infection, or inadequate post-TURBT healing disrupts the urothelial barrier. These settings increase the risk of hematogenous dissemination of live attenuated BCG. [23]" ], "bullets": [ "Suspect BCG infection when inflammatory or infectious complications extend beyond expected local cystitis, including prostatitis, epididymo-orchitis, pyelonephritis, hepatitis, pneumonitis, mycotic aneurysm, or osteoarticular infection. [23]", "BCG infection occurs in up to 1% of treated patients and requires antimycobacterial treatment, generally with infectious diseases involvement. [23]" ] } ], "table": { "caption": "Practical treatment direction for NMIBC phenotypes. [1][14][23][24]", "columns": [ "Phenotype", "Management priority", "Key tradeoff or exception" ], "rows": [ [ "Low-grade NMIBC recurrence after BCG", "Use intravesical chemotherapy as a valid conservative option. [24]", "This pattern usually carries recurrence risk more than progression risk. [24]" ], [ "High-risk NMIBC after TURBT", "Administer intravesical BCG as standard adjuvant therapy. [1][14][23]", "Do not administer through a traumatic catheterization, with active urinary infection, or before adequate healing. [23]" ], [ "Highest-risk BCG-naive NMIBC", "Discuss radical cystectomy alongside BCG-based treatment. [14]", "Cystectomy improves oncologic certainty but has substantial quality-of-life implications. [24]" ], [ "BCG-unresponsive high-grade NMIBC", "Prioritize radical cystectomy if surgically appropriate; pembrolizumab is a bladder-sparing systemic option supported in this setting. [1][4]", "Repeated conservative therapy risks delaying definitive control of biologically aggressive disease. [24]" ] ] } }, { "id": "mibc-curative-treatment", "eyebrow": "Muscle-Invasive Disease", "heading": "Choose cystectomy-based or trimodality curative treatment", "intro": "For cT2-T4aN0M0 disease, local therapy must be integrated with systemic treatment when feasible.", "paragraphs": [ "For clinically non-metastatic muscle-invasive bladder cancer, cisplatin-based neoadjuvant chemotherapy followed by radical cystectomy is the reference curative-intent pathway. Meta-analytic evidence indicates that neoadjuvant cisplatin-based treatment reduces mortality risk by 13% and yields an absolute 5-year survival benefit of approximately 5%. [18]", "Perform radical cystectomy with bilateral pelvic lymphadenectomy when surgery is selected. TURBT remains essential for diagnosis and local debulking, but a pathologic response after neoadjuvant chemotherapy cannot be attributed entirely to chemotherapy because complete TURBT can independently downstage some tumors. [10][13]", "Offer bladder-preserving trimodality therapy to patients seeking preservation when multidisciplinary assessment supports it. The regimen combines maximal TURBT, concurrent chemotherapy, and radiation therapy; radiation alone and maximal TURBT alone are not equivalent bladder-preserving curative strategies. [13]" ], "bullets": [ "Do not substitute partial cystectomy, radiation alone, or maximal TURBT alone for standard definitive treatment except in carefully selected circumstances; these are considered separately from multimodal bladder preservation. [13]", "Explain that radical cystectomy and pelvic lymph-node dissection control localized disease, but occult micrometastatic disease contributes to subsequent distant relapse in up to 50% of patients with localized MIBC. [18]", "Use curative-intent staging and treatment planning for cT2-T4N0M0 disease; clinically metastatic disease follows a systemic-therapy-first pathway. [13][21]" ], "subsections": [], "table": { "caption": "Curative-intent options for clinically non-metastatic MIBC. [13][18]", "columns": [ "Approach", "Core components", "When it fits" ], "rows": [ [ "Cystectomy-based treatment", "Cisplatin-based neoadjuvant chemotherapy followed by radical cystectomy and bilateral pelvic lymphadenectomy. [13][18]", "Standard pathway for cT2-T4aN0M0 disease in patients eligible for cisplatin and definitive surgery. [13][18]" ], [ "Trimodality bladder preservation", "Maximal TURBT plus concurrent chemotherapy and radiation therapy. [13]", "Option for patients pursuing bladder preservation after multidisciplinary selection. [13]" ], [ "Nonmultimodal local treatment", "Radiation alone, maximal TURBT alone, or partial cystectomy. [13]", "Reserved for selected situations; not a substitute for standard cystectomy-based care or trimodality chemoradiation. [13]" ] ] } }, { "id": "node-positive-metastatic", "eyebrow": "Advanced Disease", "heading": "Use systemic therapy first when nodes or distant sites are involved", "intro": "Regional nodal disease may still warrant consolidative local treatment after systemic response.", "paragraphs": [ "For clinically node-positive bladder urothelial carcinoma, initiate multiagent systemic therapy and reassess candidacy for intensive local treatment. In observational data, high-intensity local therapy—radical cystectomy with pelvic lymph-node dissection or bladder radiation of at least 50 Gy with TURBT—combined with systemic chemotherapy was associated with improved survival compared with conservative local treatment; selection should account for baseline life expectancy and treatment response. [9]", "The optimal approach for cN+ or limited retroperitoneal nodal disease remains uncertain because these patients are often excluded from definitive-treatment trials. Cisplatin-based chemotherapy followed by cystectomy with pelvic lymph-node dissection is commonly used, while trimodality therapy is an option for patients choosing bladder preservation. [20]", "For stage IV or M1 disease, prioritize systemic therapy. Listed systemic options include enfortumab vedotin plus pembrolizumab, chemotherapy combined with immunotherapy, chemotherapy alone, or immunotherapy; use external-beam radiation, diversion, or cystectomy for palliation of uncontrolled local symptoms or as selected adjunctive local treatment. [21]" ], "bullets": [ "Obtain molecular testing for FGFR alterations when considering erdafitinib in previously treated advanced urothelial carcinoma; approximately 20% of metastatic bladder urothelial carcinomas have FGFR variants. [21]", "Use local radiation or urinary diversion when bleeding, obstruction, or other local symptoms require palliation despite systemic disease. [21]" ], "subsections": [], "table": { "caption": "Systemic-first treatment direction in advanced urothelial bladder cancer. [9][20][21]", "columns": [ "Disease extent", "Initial strategy", "Role of local treatment" ], "rows": [ [ "cN+ regional nodal disease", "Multiagent systemic chemotherapy, commonly cisplatin-based when feasible. [20]", "Consider cystectomy with pelvic lymph-node dissection or bladder-directed chemoradiation in selected patients, particularly after response. [9][20]" ], [ "Limited retroperitoneal nodal disease", "Systemic therapy first; evidence for optimal consolidation remains uncertain. [20]", "Individualize consolidative surgery or radiation in multidisciplinary review. [20]" ], [ "M1 disease", "Systemic therapy, including enfortumab vedotin plus pembrolizumab or other chemoimmunotherapy, chemotherapy, or immunotherapy options. [21]", "Use radiation, diversion, or cystectomy selectively for palliation or adjunctive local control. [21]" ] ] } }, { "id": "surveillance-escalation", "eyebrow": "Monitoring", "heading": "Detect high-grade recurrence early and restage before escalation", "intro": "Surveillance intensity should match the risk of occult high-grade recurrence and progression.", "paragraphs": [ "For NMIBC efficacy assessment frameworks, perform cystoscopy and urine cytology every 3 months and CT or MRI urography at 6- to 12-month intervals. Use blue-light or other advanced cystoscopy consistently if it was used at baseline; changing technique between examinations can confound interpretation of apparent response or recurrence. [5]", "Do not perform routine random or bladder-mapping biopsies at fixed intervals as standard care in either BCG-naive or BCG-unresponsive NMIBC. A random bladder biopsy at 12 months is an optional trial-design measure for high-risk NMIBC, not a universal surveillance mandate. [5]", "Escalate from surveillance to repeat TURBT, directed biopsy, or definitive-treatment counseling when cystoscopy identifies recurrent lesions, cytology suggests occult high-grade disease, or pathology demonstrates persistent high-grade T1 disease or carcinoma in situ after BCG. The purpose of repeat tissue assessment is to avoid misclassifying progressive disease as a manageable superficial recurrence. [5][16][24]" ], "bullets": [ "Document advanced-cystoscopy modality and findings longitudinally when using enhanced visualization. [5]", "Do not treat urinary biomarkers as stand-alone evidence of recurrence because false-positive results and incomplete large-cohort validation limit their decisional reliability. [5]" ], "subsections": [], "table": { "caption": "Surveillance findings that change the next step in NMIBC. [5][16][24]", "columns": [ "Finding", "Interpretation", "Next action" ], "rows": [ [ "Visible recurrent lesion on cystoscopy", "Requires pathologic reassessment because grade and depth determine whether conservative treatment remains appropriate. [5][16]", "Perform TURBT or directed biopsy and reclassify risk from the new pathology. [16]" ], [ "Positive or concerning urine cytology without clear lesion", "May indicate occult high-grade disease. [5]", "Use cystoscopic evaluation and tissue-directed assessment rather than relying on biomarkers alone. [5]" ], [ "Persistent or recurrent high-grade T1 disease or carcinoma in situ after BCG", "High-risk BCG failure with substantial progression concern. [24]", "Counsel regarding radical cystectomy and consider approved bladder-sparing alternatives only when definitive surgery is declined or unsuitable. [1][24]" ] ] } } ], "faq": [], "references": [ { "number": 1, "title": "Pembrolizumab monotherapy for the treatment of high-risk ...", "detail": "www.thelancet.com", "url": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00147-9/abstract", "authors": "www.thelancet.com", "host": "www.thelancet.com" }, { "number": 2, "title": "Supplementary appendix", "detail": "www.thelancet.com", "url": "https://www.thelancet.com/cms/10.1016/S1470-2045(21)00147-9/attachment/ff79b5c3-07aa-4a2b-b082-0d6b860fa0bd/mmc1.pdf", "authors": "www.thelancet.com", "host": "www.thelancet.com" }, { "number": 3, "title": "Hematuria as a Marker of Occult Urinary Tract Cancer", "detail": "annals.org", "url": "https://annals.org/aim/article/2484287/hematuria-marker-occult-urinary-tract-cancer-advice-high-value-care", "authors": "annals.org", "host": "annals.org" }, { "number": 4, "title": "BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG | Nature Reviews Urology", "detail": "www.nature.com", "url": "http://www.nature.com/articles/nrurol.2017.16.pdf", "authors": "www.nature.com", "host": "www.nature.com" }, { "number": 5, "title": "Definitions, End Points, and Clinical Trial... : Journal of Clinical Oncology", "detail": "journals.lww.com", "url": "https://journals.lww.com/00005083-202312100-00013", "authors": "journals.lww.com", "host": "journals.lww.com" }, { "number": 6, "title": "Longitudinal circulating tumour DNA identifies... : BJU International", "detail": "journals.lww.com", "url": "https://journals.lww.com/00125504-202609000-00020", "authors": "journals.lww.com", "host": "journals.lww.com" }, { "number": 7, "title": "Medicine®", "detail": "journals.lww.com", "url": "https://journals.lww.com/md-journal/_layouts/15/oaks.journals/downloadpdf.aspx?an=00005792-202503210-00036", "authors": "journals.lww.com", "host": "journals.lww.com" }, { "number": 8, "title": "Application of Electrical Impedance Tomography in ...", "detail": "journals.lww.com", "url": "https://journals.lww.com/adbm/_layouts/15/oaks.journals/downloadpdf.aspx?an=01679891-202511280-00136", "authors": "journals.lww.com", "host": "journals.lww.com" }, { "number": 9, "title": "High-intensity local treatment of clinical node-positive urothelial carcinoma of the bladder alongside systemic chemotherapy improves overall survival - ScienceDirect", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/abs/pii/S1078143921003367", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 10, "title": "Pathologic response in patients receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer: Is therapeutic effect owing to chemotherapy or TURBT? - ScienceDirect", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/abs/pii/S1078143916302149", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 11, "title": "Non Muscle Invasive Treatment of Bladder Cancer - an overview | ScienceDirect Topics", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/topics/medicine-and-dentistry/non-muscle-invasive-treatment-of-bladder-cancer", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 12, "title": "Recurrence and Progression of Disease in Non–Muscle-Invasive Bladder Cancer: From Epidemiology to Treatment Strategy - ScienceDirect", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/abs/pii/S0302283809006551", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 13, "title": "Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/SUO Guideline (2017; Amended 2020, 2024)", "detail": "www.auajournals.org", "url": "https://www.auajournals.org/doi/10.1097/JU.0000000000003981", "authors": "www.auajournals.org", "host": "www.auajournals.org" }, { "number": 14, "title": "Predicting Response to Intravesical Bacillus Calmette-Guérin in High-Risk Nonmuscle-Invasive Bladder Cancer Using an Artificial Intelligence–Powered Pathology Assay: Development and Validation in an International 12-Center Cohort", "detail": "www.auajournals.org", "url": "https://www.auajournals.org/doi/10.1097/JU.0000000000004278", "authors": "www.auajournals.org", "host": "www.auajournals.org" }, { "number": 15, "title": "Guideline for the Management of Nonmuscle Invasive Bladder Cancer (Stages Ta, T1, and Tis): 2007 Update", "detail": "www.auajournals.org", "url": "https://www.auajournals.org/doi/10.1016/j.juro.2007.09.003", "authors": "www.auajournals.org", "host": "www.auajournals.org" }, { "number": 16, "title": "Diagnosis and Treatment of Non-Muscle Invasive Bladder ...", "detail": "www.auajournals.org", "url": "https://www.auajournals.org/doi/full/10.1097/JU.0000000000003846", "authors": "www.auajournals.org", "host": "www.auajournals.org" }, { "number": 17, "title": "Webinars - UROONCO Bladder Cancer", "detail": "bladder.uroonco.uroweb.org", "url": "https://bladder.uroonco.uroweb.org?p=4144", "authors": "bladder.uroonco.uroweb.org", "host": "bladder.uroonco.uroweb.org" }, { "number": 18, "title": "Immune checkpoint inhibitor therapy as a neoadjuvant treatment for muscle-invasive bladder carcinoma: A narrative review", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12042169", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov" }, { "number": 19, "title": "Articles - UROONCO Bladder Cancer", "detail": "bladder.uroonco.uroweb.org", "url": "https://bladder.uroonco.uroweb.org/articles/page/2", "authors": "bladder.uroonco.uroweb.org", "host": "bladder.uroonco.uroweb.org" }, { "number": 20, "title": "The Role of Radical Cystectomy And Lymphadenectomy In The Management Of Bladder Cancer With Clinically Positive Lymph Node Involvement", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11617270", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov" }, { "number": 21, "title": "Bladder Cancer Treatment (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf", "detail": "www.ncbi.nlm.nih.gov", "url": "https://www.ncbi.nlm.nih.gov/books/NBK65962", "authors": "www.ncbi.nlm.nih.gov", "host": "www.ncbi.nlm.nih.gov" }, { "number": 22, "title": "Videos - UROONCO Bladder Cancer", "detail": "bladder.uroonco.uroweb.org", "url": "https://bladder.uroonco.uroweb.org/videos/page/2", "authors": "bladder.uroonco.uroweb.org", "host": "bladder.uroonco.uroweb.org" }, { "number": 23, "title": "BCG in Bladder Cancer Immunotherapy - PMC", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9264881", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov" }, { "number": 24, "title": "The management of BCG failure in non-muscle-invasive bladder cancer: an update", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC2792453", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov" } ], "editorialNote": "Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.", "citations": [ { "number": 1, "title": "Pembrolizumab monotherapy for the treatment of high-risk ...", "detail": "www.thelancet.com", "url": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00147-9/abstract", "authors": "www.thelancet.com", "host": "www.thelancet.com", "snippet": "by AV Balar · 2021 · Cited by 664 — Standard treatment for high-risk non-muscle-invasive bladder cancer is transurethral resection of bladder tumour followed by intravesical BCG immunotherapy.", "score": 0.25053254 }, { "number": 2, "title": "Supplementary appendix", "detail": "www.thelancet.com", "url": "https://www.thelancet.com/cms/10.1016/S1470-2045(21)00147-9/attachment/ff79b5c3-07aa-4a2b-b082-0d6b860fa0bd/mmc1.pdf", "authors": "www.thelancet.com", "host": "www.thelancet.com", "snippet": "May 26, 2026 — Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, ...Read more", "score": 0.20377128 }, { "number": 3, "title": "Hematuria as a Marker of Occult Urinary Tract Cancer", "detail": "annals.org", "url": "https://annals.org/aim/article/2484287/hematuria-marker-occult-urinary-tract-cancer-advice-high-value-care", "authors": "annals.org", "host": "annals.org", "snippet": "The presence of blood in the urine, or hematuria, is a common finding in clinical practice and can sometimes be a sign of occult cancer.", "score": 0.12978853 }, { "number": 4, "title": "BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG | Nature Reviews Urology", "detail": "www.nature.com", "url": "http://www.nature.com/articles/nrurol.2017.16.pdf", "authors": "www.nature.com", "host": "www.nature.com", "snippet": "Article \nCAS \nPubMed \nPubMed Central \nGoogle Scholar\n\nMorales, A. et al. Efficacy and safety of MCNA in patients with nonmuscle invasive bladder cancer at high risk for recurrence and progression rin after failed treatment with bacillus Calmette–Guerin. J. Urol. 193, 1135–1143 (2015).\n\nArticle \nCAS", "score": 0.6994397 }, { "number": 5, "title": "Definitions, End Points, and Clinical Trial... : Journal of Clinical Oncology", "detail": "journals.lww.com", "url": "https://journals.lww.com/00005083-202312100-00013", "authors": "journals.lww.com", "host": "journals.lww.com", "snippet": "Baseline evaluation for NMIBC studies should include bladder cancer history detailing the date of initial diagnosis, grade, stage, multiplicity, tumor size, number of prior recurrences, previous treatment history, and detailed cystoscopic findings including tumor appearance with accompanying cystosc", "score": 0.5158888 }, { "number": 6, "title": "Longitudinal circulating tumour DNA identifies... : BJU International", "detail": "journals.lww.com", "url": "https://journals.lww.com/00125504-202609000-00020", "authors": "journals.lww.com", "host": "journals.lww.com", "snippet": "Non-muscle-invasive bladder cancer (NMIBC) accounts for most newly diagnosed bladder cancers and continues to present major therapeutic challenges. Recurrence is frequent and every fifth patient with high-risk disease progresses to MIBC despite intravesical therapy [1][2][3]. Emerging artificial int", "score": 0.50388235 }, { "number": 7, "title": "Medicine®", "detail": "journals.lww.com", "url": "https://journals.lww.com/md-journal/_layouts/15/oaks.journals/downloadpdf.aspx?an=00005792-202503210-00036", "authors": "journals.lww.com", "host": "journals.lww.com", "snippet": "Computed tomography urography for diagnosing bladder cancer. BJU Int ... CT cystoscopy: an innovation in bladder imaging. AJR Am J", "score": 0.42620277 }, { "number": 8, "title": "Application of Electrical Impedance Tomography in ...", "detail": "journals.lww.com", "url": "https://journals.lww.com/adbm/_layouts/15/oaks.journals/downloadpdf.aspx?an=01679891-202511280-00136", "authors": "journals.lww.com", "host": "journals.lww.com", "snippet": "by ZR Gatabi · 2025 · Cited by 1 — Currently, several techniques are available to diagnose bladder cancer, including CT scan and MRI, ultrasound scans, excretory urography,", "score": 0.338493 }, { "number": 9, "title": "High-intensity local treatment of clinical node-positive urothelial carcinoma of the bladder alongside systemic chemotherapy improves overall survival - ScienceDirect", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/abs/pii/S1078143921003367", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "# Clinical-bladder cancer High-intensity local treatment of clinical node-positive urothelial carcinoma of the bladder alongside systemic chemotherapy improves overall survival. Role of local treatment (LT) alongside systemic chemotherapy in clinical node-positive bladder cancer is unclear. We ident", "score": 0.559411 }, { "number": 10, "title": "Pathologic response in patients receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer: Is therapeutic effect owing to chemotherapy or TURBT? - ScienceDirect", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/abs/pii/S1078143916302149", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "# Original article Pathologic response in patients receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer: Is therapeutic effect owing to chemotherapy or TURBT?☆. We estimate that 38% of pathologic response in patients who receive NAC for muscle-invasive bladder cancer can be attribut", "score": 0.51603514 }, { "number": 11, "title": "Non Muscle Invasive Treatment of Bladder Cancer - an overview | ScienceDirect Topics", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/topics/medicine-and-dentistry/non-muscle-invasive-treatment-of-bladder-cancer", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "Title: Non Muscle Invasive Treatment of Bladder Cancer - an overview | ScienceDirect Topics\nThe treatment of NMIBC (Non-Muscle Invasive Bladder Cancer) is defined as a therapeutic approach that typically includes transurethral resection of bladder tumor (TURBT) followed by intravesical chemotherapy ", "score": 0.80771893 }, { "number": 12, "title": "Recurrence and Progression of Disease in Non–Muscle-Invasive Bladder Cancer: From Epidemiology to Treatment Strategy - ScienceDirect", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/abs/pii/S0302283809006551", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "Title: Recurrence and Progression of Disease in Non–Muscle-Invasive Bladder Cancer: From Epidemiology to Treatment Strategy - ScienceDirect\n# Collaborative Review – Bladder Cancer Recurrence and Progression of Disease in Non–Muscle-Invasive Bladder Cancer: From Epidemiology to Treatment Strategy. Th", "score": 0.783542 }, { "number": 13, "title": "Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/SUO Guideline (2017; Amended 2020, 2024)", "detail": "www.auajournals.org", "url": "https://www.auajournals.org/doi/10.1097/JU.0000000000003981", "authors": "www.auajournals.org", "host": "www.auajournals.org", "snippet": "The full evidence-based guideline for clinically non-metastatic muscle-invasive urothelial bladder cancer (cT2-T4N0M0) focuses on the evaluation, treatment, and surveillance of MIBC and is guided toward curative intent. The treatment of patients with clinically evident metastatic bladder cancer is o", "score": 0.79369855 }, { "number": 14, "title": "Predicting Response to Intravesical Bacillus Calmette-Guérin in High-Risk Nonmuscle-Invasive Bladder Cancer Using an Artificial Intelligence–Powered Pathology Assay: Development and Validation in an International 12-Center Cohort", "detail": "www.auajournals.org", "url": "https://www.auajournals.org/doi/10.1097/JU.0000000000004278", "authors": "www.auajournals.org", "host": "www.auajournals.org", "snippet": "1. . Bladder cancer: a review. JAMA.2020; 324(19):1980-1991. doi: 10.1001/jama.2020.17598Crossref, Medline,Google Scholar\n 2. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline. J Urol.2016; 196(4):1021-1029. doi: 10.1016/j.juro.2016.06.049Link,Google Scholar\n 3. Eu", "score": 0.7471924 }, { "number": 15, "title": "Guideline for the Management of Nonmuscle Invasive Bladder Cancer (Stages Ta, T1, and Tis): 2007 Update", "detail": "www.auajournals.org", "url": "https://www.auajournals.org/doi/10.1016/j.juro.2007.09.003", "authors": "www.auajournals.org", "host": "www.auajournals.org", "snippet": "with Bacillus Calmette-Guérin: Results of a Retrospective Multicenter Study of 2451 PatientsEuropean Urology, 10.1016/j.eururo.2014.06.040, VOL. 67, NO. 1, (74-82), Online publication date: 1-Jan-2015. Anderson C, Musser J, Sfakianos J and Herr H(2015)Bladder Tumors: Association with Upper Tract N", "score": 0.7116118 }, { "number": 16, "title": "Diagnosis and Treatment of Non-Muscle Invasive Bladder ...", "detail": "www.auajournals.org", "url": "https://www.auajournals.org/doi/full/10.1097/JU.0000000000003846", "authors": "www.auajournals.org", "host": "www.auajournals.org", "snippet": "## Abstract\n\n## Purpose:\n\nThe purpose of this American Urological Association (AUA)/Society of Urologic Oncology (SUO) guideline amendment is to provide a useful reference on the effective evidence-based treatment strategies for non-muscle invasive bladder cancer (NMIBC).\n\n## Materials and Methods:\n", "score": 0.69573146 }, { "number": 17, "title": "Webinars - UROONCO Bladder Cancer", "detail": "bladder.uroonco.uroweb.org", "url": "https://bladder.uroonco.uroweb.org?p=4144", "authors": "bladder.uroonco.uroweb.org", "host": "bladder.uroonco.uroweb.org", "snippet": "Title: Webinars - UROONCO Bladder Cancer\n## EAU Edu Platform on Bladder Cancer. UROwebinar: Beyond the hype - Is it prime time for biomarkers in bladder cancer? (neo)adjuvant therapy, 5-α reductase inhibitors, Androgen antagonists, Article of the Month, ASCO GU21, ASCO GU22, ASCO21, AUA21, BCG, BCG ", "score": 0.64128816 }, { "number": 18, "title": "Immune checkpoint inhibitor therapy as a neoadjuvant treatment for muscle-invasive bladder carcinoma: A narrative review", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12042169", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov", "snippet": "## . Although surgical procedures such as radical cystectomy (RC) and pelvic lymph node dissection are effective in treating localized MIBC lesions, up to 50% of patients eventually develop distant metastases due to occult micrometastases.[1][2] Therefore, appropriate perioperative treatment requires", "score": 0.5957048 }, { "number": 19, "title": "Articles - UROONCO Bladder Cancer", "detail": "bladder.uroonco.uroweb.org", "url": "https://bladder.uroonco.uroweb.org/articles/page/2", "authors": "bladder.uroonco.uroweb.org", "host": "bladder.uroonco.uroweb.org", "snippet": "Title: Articles - UROONCO Bladder Cancer\n(neo)adjuvant therapy, 5-α reductase inhibitors, Androgen antagonists, Article of the Month, ASCO GU21, ASCO GU22, ASCO21, AUA21, BCG, BCG therapy, BCG-unresponsive disease, Bladder cancer, Bladder neoplasms, Bladder-sparing therapy, Bladder-sparing trimodali", "score": 0.568057 }, { "number": 20, "title": "The Role of Radical Cystectomy And Lymphadenectomy In The Management Of Bladder Cancer With Clinically Positive Lymph Node Involvement", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11617270", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov", "snippet": "## is cisplatin-based neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC) with pelvic lymph node dissection (PLND), although trimodality therapy (TMT) is an option for patients seeking bladder-sparing management. This approach has demonstrated 5-year overall survival (OS) rates of 55", "score": 0.55565286 }, { "number": 21, "title": "Bladder Cancer Treatment (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf", "detail": "www.ncbi.nlm.nih.gov", "url": "https://www.ncbi.nlm.nih.gov/books/NBK65962", "authors": "www.ncbi.nlm.nih.gov", "host": "www.ncbi.nlm.nih.gov", "snippet": "| Neoadjuvant combination chemotherapy followed by radical cystectomy |\n| Radical cystectomy followed by adjuvant chemotherapy or immunotherapy |\n| EBRT with or without concomitant chemotherapy |\n| Segmental cystectomy (in selected patients) |\n| TUR with fulguration (in selected patients) |\n| Stage ", "score": 0.5407062 }, { "number": 22, "title": "Videos - UROONCO Bladder Cancer", "detail": "bladder.uroonco.uroweb.org", "url": "https://bladder.uroonco.uroweb.org/videos/page/2", "authors": "bladder.uroonco.uroweb.org", "host": "bladder.uroonco.uroweb.org", "snippet": "Title: Videos - UROONCO Bladder Cancer\n## EAU Edu Platform on Bladder Cancer. 23rd Meeting of the EAU Robotic Urology Section. ## Tags. (neo)adjuvant therapy, 5-α reductase inhibitors, Androgen antagonists, Article of the Month, ASCO GU21, ASCO GU22, ASCO21, AUA21, BCG, BCG therapy, BCG-unresponsive", "score": 0.5405607 }, { "number": 23, "title": "BCG in Bladder Cancer Immunotherapy - PMC", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9264881", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov", "snippet": "Additional complications are the result of the establishment of a persistent BCG infection. These include local spread of BCG resulting in cystitis, prostatitis, epididymo-orchitis, or, rarely, pyelonephritis. More infrequently, BCG can spread to distant organs, resulting in hepatitis, pneumonitis, ", "score": 0.52203226 }, { "number": 24, "title": "The management of BCG failure in non-muscle-invasive bladder cancer: an update", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC2792453", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov", "snippet": "The European Association of Urology (EAU) guidelines on bladder cancer recommend BCG for intermediate-risk patients for whom intravesical chemotherapy is unsuccessful and as the first treatment choice in high-risk patients.3 However, the EAU guidelines recommend intravesical chemotherapy in low-risk", "score": 0.51383984 } ], "publishedAt": "2026-08-24T17:04:20.655981+00:00", "updatedAt": "2026-08-24T17:04:20.655981+00:00", "readingMinutes": 6, "slug": "bladder-cancer" }